Online Broadcaster Confirms Major Merger As Regulations Relax

This week’s dividend landscape is buzzing with activity. Media mergers, regulatory rulings, and shifting dividend payouts are shaping investor sentiment.

Here’s a round-up of the latest developments to keep a close eye on.

Never Miss a Stock Recommendation Again!

We now send our dividend picks right to your phone via text, so you’ll get the same actionable moves without having to open your inbox.

👉 Click here to get our dividend picks by text and keep our content right at your fingertips.

Utilities

Duke Energy (NYSE: DUK) Moves to Merge Carolina Subsidiaries, Targeting $1B in Savings

Duke Energy (NYSE: DUK) has formally asked regulators to merge its North and South Carolina utility subsidiaries into a single entity, projecting more than $1 billion in customer savings over the next decade.

The consolidation of Duke Energy Carolinas and Duke Energy Progress would streamline operations across 4.7 million customers and 34,600 megawatts of capacity.

For investors, the move signals more than just administrative efficiency.

Consolidating regulatory filings and rate structures removes duplicative costs and unlocks scale advantages, both of which strengthen Duke’s margin profile in a capital-intensive sector. 

Utilities are valued for steady dividends and reliable cash flows, and reducing long-term cost burdens improves the company’s ability to protect payouts even as it faces rising capital requirements tied to grid modernization and renewable integration.

Potential new shareholders should view this as an efficiency-driven play in a sector where regulatory approval often dictates growth. 

If regulators grant the request, Duke could set a precedent for other utilities exploring similar consolidation strategies.

As the regulatory process unfolds, investors will be watching how the company balances customer savings with shareholder returns, and whether the merger accelerates Duke’s positioning as a dominant Southeastern utility with cleaner operations and more predictable earnings.

DUK currently trades at $125 and pays a dividend of $4.18 per share, a yield of 3.35%.

Restaurants & Dining

McDonald’s Revives ‘Extra Value Meals’ in Bid to Restore Traffic and Loyalty

McDonald’s (NYSE: MCD) will slash prices on popular combo meals this fall, marking its most aggressive push in years to reclaim its reputation for value dining.

Eight of the chain’s best-selling meal bundles will be priced roughly 15% lower than the sum of their items, with options like the Big Mac meal dropping to $8 and breakfast staples reintroduced at the $5 level.

For investors, the move represents a calculated trade-off: slimmer margins on each combo, but the potential for a broader traffic rebound.

The company has recently faced pushback from customers frustrated by rising menu costs, particularly lower-income diners who historically formed the backbone of its U.S. sales.

By leaning into affordability, McDonald’s is positioning itself against not only Burger King and Wendy’s, but also fast-casual rivals that have steadily poached price-conscious customers.

If the initiative succeeds, it could restore McDonald’s volume growth while reinforcing brand loyalty at a critical moment when competitors are expanding their discount platforms.

The rebranding of these bundles under the legacy “Extra Value Meals” banner adds a nostalgic touch, signaling that the company is listening to its base.

The coming quarters will reveal whether this renewed focus on affordability delivers the dual payoff of customer goodwill and sustainable investor confidence.

MCD currently trades at $314 and pays a dividend of $7.08 per share, a yield of 2.25%.

Don’t Settle Now (Sponsored)

Think Your Portfolio’s Good? These 5 Picks Aim Higher

The market’s been generous lately. But why settle for average gains when extraordinary is right there?

A new special report reveals 5 stock setups with the potential to double in value over the next 12 months — backed by solid research and powerful indicators.

These are the kind of companies that can transform a “decent” portfolio into a “wow” one.

It’s free to download, but only for a few more hours.

[Get It Before Midnight]

*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.

Pharmaceuticals & Biotechnology

AbbVie Completes Capstan Acquisition, Gaining First-in-Class Autoimmune Therapy Candidate

AbbVie (NYSE: ABBV) has completed its acquisition of Capstan Therapeutics, adding a potential first-in-class in vivo CAR-T candidate and a proprietary lipid nanoparticle (tLNP) platform designed for targeted RNA delivery.

Capstan’s lead asset, CPTX2309, is currently in Phase 1 for B-cell-mediated autoimmune diseases and aims to deliver drug-free, durable remissions without the toxicities associated with traditional CAR-T treatments.

Upon examining the acquisition, it’s clear that this goes far beyond a pipeline bolt-on. AbbVie is strengthening its immunology portfolio at a time when its legacy blockbuster, Humira, is in decline and biosimilar pressures are weighing on revenue.

By acquiring Capstan, AbbVie secures both a high-potential autoimmune therapy and a technology platform that could extend into multiple therapeutic areas, including oncology and rare diseases.

This positions the company not just as a follower in cell therapy but as a potential category re-definer in in vivo programming.

Shareholders will be watching closely to see whether AbbVie can translate this scientific edge into commercial durability, especially as competition intensifies from rivals like Bristol Myers and Novartis.

The acquisition underscores AbbVie’s strategy of building depth in immunology while diversifying into next-generation platforms.

If successful, the Capstan deal could provide AbbVie with both new revenue streams and a hedge against looming patent cliffs.

ABBV currently trades at $210 and pays a dividend of $6.56 per share, a yield of 3.12%.

ECO has increased its dividend payment to 70 cents per share, a rise of 118.75%. Its new yield is 10.8%.

MGE has boosted its dividend payout to 48 cents per share, an increase of 5.56%. Its new yield is 2.2%.

DEO has lifted its dividend payment to $2.52 per share, an increase of 55.51%. Its new yield is 3.7%.

SFL has cut its dividend payment to 20 cents per share, a reduction of 25.93%. Its new yield is 8.77%. 

WHR has trimmed its dividend payment to 90 cents per share, a drop of 48.57%. Its new yield is 4.08%. 

TAIT has reduced its dividend payment to 3 cents per share, a decline of 30%. Its new yield is 6.4%.

Strength Mid Shift (Sponsored)

Your Guide to Market Leaders in a Time of Uncertainty

Volatility is high, but opportunity still exists — if you know where to look.

This free report features seven stocks identified by deep research and forward-looking analysis.

Each one is positioned to outperform in this unique market cycle.

It’s not about hype — it’s about strategy.

[Get your free copy now.]

Everything Else

• Best Buy has launched a new third-party marketplace, which will give website and app shoppers access to additional brands as it strives to boost sales.

• Comcast will spin off MSNBC later this year into a separate corporate entity. With that move, the broadcaster will change its name to MS NOW and debut a new logo.

• Northwestern Energy will merge with Black Hills to create a new regional regulated electric and natural gas utility company. 

• Luxury automaker Cadillac, which is part of the General Motors family, has launched a new custom paint option with 160 exterior colors to choose from.